<DOC>
	<DOCNO>NCT01019278</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy , proton beam radiotherapy , delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give proton beam radiation therapy together cisplatin work treat patient stage IB , stage II , stage III , stage IVA cervical cancer positive lymph node .</brief_summary>
	<brief_title>Proton Beam Radiation Therapy Cisplatin Treating Patients With Stage IB , Stage II , Stage III , Stage IVA Cervical Cancer Positive Lymph Nodes</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility proton beam radiotherapy patient cervical cancer FDG-positive para-aortic lymph node . SECONDARY OBJECTIVES : I . To determine incidence acute toxicity concurrent weekly cisplatin chemotherapy addition pelvic para-aortic irradiation use proton radiotherapy intracavitary brachytherapy patient carcinoma uterine cervix pelvic para-aortic nodal involvement demonstrate FDG-PET . II . To assess late complication irradiation use proton beam therapy place conventional photon beam therapy . III . To compare dose distribution tumor surround normal structure use DVHs ( Dose Volume Histograms ) generate proton plan use treat patient photon plan generate comparison purpose . IV . To evaluate whether benefit concurrent weekly cisplatin chemotherapy addition pelvic para-aortic proton beam radiotherapy intracavitary brachytherapy evidence time local failure , time distant failure , time failure overall survival patient carcinoma uterine cervix pelvic para-aortic nodal involvement demonstrate FDG-PET . OUTLINE : Patients undergo CT , MRI , FDG-PET image scan radiotherapy treatment planning . Patients undergo external proton beam radiotherapy daily , 5 time per week , 9 week . Patients also receive cisplatin IV weekly 6 week radiotherapy . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion Patients must histologically document carcinoma uterine cervix FIGO Stage IB IVA Patients must distant metastasis apart positive lymph node FDG PET Patients must Karnofsky Performance Status &gt; = 60 Treatment plan include cisplatin patient medical contraindication administration cisplatin Adequate bone marrow function : WBC &gt; = 3000/mm^3 ; platelet &gt; = 75,000 mm^3 Adequate renal function : creatinine = &lt; 2.0 mg/dl ( urinary diversion permit improve renal function ) Patients must bilirubin = &lt; 1.5 mg/dl Ability understand willingness sign write informed consent document Exclusion FDG PET Scan evidence distant disease No prior surgery treatment disease exploratory laparotomy biopsy allow No previous systemic chemotherapy allow No prior pelvic radiation therapy permit transvaginal irradiation control bleed allow Women childbearing potential positive result screen serum pregnancy test</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>